Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2014.09.207 ◽

2014 ◽

Vol 3 (6) ◽

pp. 761-762 ◽

Cited By ~ 2

Author(s):

X. Montalban ◽

J.S. Inshasi ◽

A.J. Coles ◽

H.P. Hartung ◽

E. Havrdova ◽

...

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Treatment Naïve ◽

Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2014.09.194 ◽

2014 ◽

Vol 3 (6) ◽

pp. 756 ◽

Cited By ~ 1

Author(s):

B.C. Kieseier ◽

M.A. Sahraian ◽

A.J. Coles ◽

H.P. Hartung ◽

E. Havrdova ◽

...

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Prior Therapy ◽

Relapsing Remitting ◽

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): Interim analysis of a phase II extension trial in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8951c5 ◽

2017 ◽

Author(s):

Eva Havrdova

Keyword(s):

Multiple Sclerosis ◽

Phase Ii ◽

Interim Analysis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Extension Trial

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Case Medical Research ◽

10.31525/ct1-nct03846219 ◽

2000 ◽

Author(s):

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial

Frontiers in Behavioral Neuroscience ◽

10.3389/fnbeh.2016.00028 ◽

2016 ◽

Vol 10 ◽

Cited By ~ 11

Author(s):

Flavia Mattioli ◽

Fabio Bellomi ◽

Chiara Stampatori ◽

Leandro Provinciali ◽

Laura Compagnucci ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Cognitive Training ◽

Domain Specific ◽

Relapsing Remitting ◽

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286418796404 ◽

2018 ◽

Vol 11 ◽

pp. 175628641879640 ◽

Cited By ~ 6

Author(s):

Emanuele D’Amico ◽

Aurora Zanghì ◽

Graziella Callari ◽

Giovanna Borriello ◽

Antonio Gallo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Comparable Efficacy ◽

Real Word ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286420968357 ◽

2020 ◽

Vol 13 ◽

pp. 175628642096835

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Safety And Efficacy ◽

Delayed Release ◽

Relapsing Remitting ◽

Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2019.11.063 ◽

2020 ◽

Vol 37 ◽

pp. 101588

Author(s):

Patrick Vermersch ◽

Juha-Pekka Erälinna ◽

Richard Nicholas ◽

Celia Oreja-Guevara ◽

Aksel Siva ◽

...

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis ◽

Previous Disease